Goldman Sachs Group Inc Infinity Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.46 - $1.21 $22,712 - $59,743	-49,375 Reduced 66.06%	25,367 $14,000
Q4 2022 Feb 13, 2023	SELL	$0.46 - $1.21 $22,712 - $59,743	-49,375 Reduced 66.06%	25,367 $14,000
Q3 2022 May 14, 2024	SELL	$0.59 - $1.7 $93,053 - $268,120	-157,718 Reduced 67.85%	74,742 $89,000
Q3 2022 Nov 10, 2022	SELL	$0.59 - $1.7 $93,053 - $268,120	-157,718 Reduced 67.85%	74,742 $0
Q2 2022 May 14, 2024	BUY	$0.49 - $1.2 $113,905 - $278,952	232,460 New	232,460 $147,000
Q2 2022 Aug 15, 2022	BUY	$0.49 - $1.2 $12,909 - $31,614	26,345 Added 12.78%	232,460 $147,000
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $30,403 - $85,845	-35,769 Reduced 14.79%	206,115 $235,000
Q4 2021 Feb 14, 2022	BUY	$1.86 - $3.36 $60,414 - $109,136	32,481 Added 15.51%	241,884 $544,000
Q3 2021 Nov 10, 2021	BUY	$1.52 - $3.82 $318,292 - $799,919	209,403 New	209,403 $716,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.